Photodynamic therapy for neovascular age‐related macular degeneration

Richard PL Wormald; Jennifer R Evans; Liam L Smeeth; Katherine S Henshaw

doi:10.1002/14651858.CD002030.pub2

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Guías
Temas

Revisiones y protocolos relacionados

Topics

Temas

Analysis 1.1

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 1 Overall effect: >=3 lines lost at 12 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 2 Overall effect: >=3 lines lost at 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 3 Overall effect: >=6 lines lost at 12 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 4 Overall effect: >=6 lines lost at 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 5 Classic CNV subgroups: >=3 lines lost at 12 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 6 Classic CNV subgroups: >=3 lines lost at 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 7 Overall effect: contrast sensitivity: >= 6 letters lost at 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 8 Overall effect: contrast sensitivity: >= 15 letters lost at 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 9 Adverse effects: acute severe visual acuity decrease.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.10

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 10 Adverse effects: visual disturbance.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.11

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 11 Adverse effects: injection site.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.12

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 12 Adverse effects: infusion‐related back pain.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.13

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 13 Adverse effects: allergic reactions.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.14

Comparison 1 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO, Outcome 14 Adverse effects: photosensitivity reactions.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall effect: >=3 lines lost at 12 months Show forest plot	2	948	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.70, 0.91]

2 Overall effect: >=3 lines lost at 24 months Show forest plot	2	948	Risk Ratio (M‐H, Fixed, 95% CI)	0.77 [0.69, 0.87]

3 Overall effect: >=6 lines lost at 12 months Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

4 Overall effect: >=6 lines lost at 24 months Show forest plot	2	948	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.50, 0.76]

5 Classic CNV subgroups: >=3 lines lost at 12 months Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

5.1 No classic CNV	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.2 Classic CNV > 0% to < 50%	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.3 Classic CNV > 50% (predominantly classic)	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Classic CNV subgroups: >=3 lines lost at 24 months Show forest plot	2	942	Risk Ratio (M‐H, Fixed, 95% CI)	0.77 [0.69, 0.87]

6.1 No classic CNV	2	319	Risk Ratio (M‐H, Fixed, 95% CI)	0.77 [0.64, 0.92]
6.2 Classic CNV > 0 to < 50%	2	362	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.77, 1.14]
6.3 Classic CNV > 50% (predominantly classic)	2	261	Risk Ratio (M‐H, Fixed, 95% CI)	0.60 [0.48, 0.75]
7 Overall effect: contrast sensitivity: >= 6 letters lost at 24 months Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

8 Overall effect: contrast sensitivity: >= 15 letters lost at 24 months Show forest plot	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected

9 Adverse effects: acute severe visual acuity decrease Show forest plot	2	948	Risk Difference (M‐H, Fixed, 95% CI)	0.02 [0.01, 0.03]

10 Adverse effects: visual disturbance Show forest plot	2	948	Risk Ratio (M‐H, Fixed, 95% CI)	1.61 [1.24, 2.09]

11 Adverse effects: injection site Show forest plot	2	948	Odds Ratio (M‐H, Fixed, 95% CI)	2.54 [1.50, 4.31]

12 Adverse effects: infusion‐related back pain Show forest plot	2	948	Odds Ratio (M‐H, Fixed, 95% CI)	8.40 [1.11, 63.58]

13 Adverse effects: allergic reactions Show forest plot	2	948	Odds Ratio (M‐H, Fixed, 95% CI)	0.94 [0.34, 2.56]

14 Adverse effects: photosensitivity reactions Show forest plot	2	948	Odds Ratio (M‐H, Fixed, 95% CI)	5.37 [1.01, 28.60]

Comparison 1. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet